Two Sigma Advisers LP Boosts Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Two Sigma Advisers LP increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 14.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,499,812 shares of the biotechnology company's stock after buying an additional 318,800 shares during the period. Two Sigma Advisers LP owned 1.21% of BioCryst Pharmaceuticals worth $18,799,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Two Sigma Investments LP boosted its holdings in BioCryst Pharmaceuticals by 0.8% in the 4th quarter. Two Sigma Investments LP now owns 1,774,214 shares of the biotechnology company's stock valued at $13,342,000 after purchasing an additional 13,406 shares during the period. Sherbrooke Park Advisers LLC increased its position in BioCryst Pharmaceuticals by 25.9% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 34,628 shares of the biotechnology company's stock worth $260,000 after purchasing an additional 7,134 shares in the last quarter. ProShare Advisors LLC increased its position in BioCryst Pharmaceuticals by 32.6% during the 4th quarter. ProShare Advisors LLC now owns 68,004 shares of the biotechnology company's stock worth $511,000 after purchasing an additional 16,732 shares in the last quarter. Quantinno Capital Management LP increased its position in BioCryst Pharmaceuticals by 38.2% during the 4th quarter. Quantinno Capital Management LP now owns 14,828 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 4,097 shares in the last quarter. Finally, Man Group plc grew its holdings in BioCryst Pharmaceuticals by 46.3% during the 4th quarter. Man Group plc now owns 89,954 shares of the biotechnology company's stock worth $676,000 after acquiring an additional 28,481 shares during the last quarter. Institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded up $0.32 on Tuesday, hitting $10.91. The stock had a trading volume of 1,326,258 shares, compared to its average volume of 3,020,143. The business has a 50 day moving average of $8.44 and a 200 day moving average of $8.07. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of -17.88 and a beta of 1.08. BioCryst Pharmaceuticals, Inc. has a 12-month low of $5.92 and a 12-month high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. BioCryst Pharmaceuticals's revenue was up 40.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.28 EPS. As a group, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BCRX shares. JPMorgan Chase & Co. boosted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Tuesday, May 6th. JMP Securities reissued a "market outperform" rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Needham & Company LLC boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $13.00 target price (up from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.